Anvil Diagnostics

Anvil Diagnostics aims to revolutionize microbial diagnostics for precision medicine by developing efficient and scalable DNA detection technologies. The company's unconventional statistically motivated assays upgrade the capabilities of existing digital PCR systems, promising a new generation of accessible and routine diagnostics for complex conditions. Anvil's first focus is on developing a rapid assay for critically ill patients that can detect and quantify hundreds of pathogens and genetic markers directly from a blood sample, addressing the current diagnostic challenges that often result in treatment delays or uncertainties. With its Seed Round investment at 01 January 2023 led by SeedFolio, Anvil Diagnostics is poised to make significant strides in the biotechnology industry. This venture, founded in 2022 in the United States, is one to watch for those passionate about the convergence of data science and molecular biology in the healthcare sector.